E-LIB Suche - Ergebnisse für: Loftus, E V J

1

P860 The Costs of Inflammatory Bowel Diseases in High-Incom..:

Burisch, J ; Zhao, M ; Odes, S...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i983-i983 , 2023

Link: https://doi.org/10.1093/..

2

P370 Maintenance of health-related quality of life improvem..:

Panés, J ; Loftus, E V J ; Higgins, P...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i373-i374 , 2022

Link: https://doi.org/10.1093/..

3

P495 Perianal fistula closure in patients receiving ustekin..:

Peyrin-Biroulet, L ; Panaccione, R ; Gasink, C...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i460-i460 , 2022

Link: https://doi.org/10.1093/..

4

DOP44 Long-term use of ozanimod in patients with moderately..:

Danese, S ; Colombel, J F ; Ponich, T...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i093-i094 , 2022

Link: https://doi.org/10.1093/..

5

DOP006 A multicentre cohort study to assess the safety of v..:

Meserve, J ; Aniwan, S ; Koliani-Pace, J L...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S034-S034 , 2018

Link: https://doi.org/10.1093/..

6

P422 Sustained corticosteroid-free remission with vedolizum..:

Loftus, E V ; Sands, B E ; Colombel, J -F...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S317-S318 , 2018

Link: https://doi.org/10.1093/..

7

A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENAN..:

Loftus, E V ; Sattin, B D ; Jacobstein, D...
Journal of the Canadian Association of Gastroenterology. 1 (2018) suppl_2 - p. 153-154 , 2018

Link: https://doi.org/10.1093/..

8

OP025 Comparative effectiveness of vedolizumab and tumour n..:

Bohm, M ; Sagi, S V ; Fischer, M...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S018-S018 , 2018

Link: https://doi.org/10.1093/..

9

DOP009 Comparative safety profile of vedolizumab and tumour..:

Lukin, D ; Weiss, A ; Aniwan, S...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S036-S036 , 2018

Link: https://doi.org/10.1093/..

10

DOP051 Shorter disease duration is associated with higher r..:

Faleck, D ; Winters, A ; Chablaney, S...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S066-S066 , 2018

Link: https://doi.org/10.1093/..

11

DOP053 Impact of concomitant immunomodulator use on vedoliz..:

Hudesman, D ; Chang, S ; Shashi, P...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S067-S068 , 2018

Link: https://doi.org/10.1093/..

12

P466 Real world effectiveness of vedolizumab over one year ..:

Schreiber, S. ; Dignass, A. ; Peyrin-Biroulet, L....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S315-S315 , 2017

Link: https://doi.org/10.1093/..

13

P209 Long-term effectiveness and safety of vedolizumab in p..:

Loftus, E.V. ; Colombel, J.-F. ; Feagan, B....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S182-S183 , 2017

Link: https://doi.org/10.1093/..

14

Immune modulator therapy for microscopic colitis in a case ..:

Cotter, T. G. ; Kamboj, A. K. ; Hicks, S. B....
Alimentary Pharmacology & Therapeutics. 46 (2017) 2 - p. 169-174 , 2017

Link: https://doi.org/10.1111/..

15

DOP021 Long-term effectiveness and safety of vedolizumab in..:

Vermeire, S. ; Loftus, E.V. ; Colombel, J.-F....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S39-S39 , 2017

Link: https://doi.org/10.1093/..